FDA Approves Oral GLP-1 Foundayo via Expedited Pathway

Key Takeaways:

• The FDA announcement describes Foundayo’s approval under the CNPV pilot, characterizing it as the first new molecular entity approved through the program.
• The release outlines labeled use for chronic weight management and a once-daily oral dosing approach with stepwise titration.
• The announcement focuses on regulatory and labeling details and does not include pricing or payer coverage information.

In an FDA press announcement, the agency stated it approved Foundayo (orforglipron) on April 1, 2026, through the Commissioner’s National Priority Voucher (CNPV) pilot, framing the decision within an expedited review pathway. The announcement reports the application was approved 50 days after filing and 294 days ahead of its PDUFA date, and it characterizes the action as the first new molecular entity approved under the pilot, as well as the fastest such approval in decades. It also summarizes the program as described in the release and outlines key elements of the product’s labeled use.

The release describes the CNPV pilot, launched in 2025, as a program for applications the agency considers aligned with national priorities. As presented in the announcement, the pilot includes enhanced communication between the FDA and sponsors and a flexible, iterative review process intended to support faster assessment. The agency describes a target decision timeline of approximately two months, while noting that review timelines may be extended if additional scientific evaluation is required. The announcement also notes that the FDA plans a public meeting and will accept written comments through June 29, 2026, as part of ongoing evaluation of the pilot.

In the same announcement, the FDA describes Foundayo (orforglipron) as an oral, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist and identifies Eli Lilly and Company as the sponsor. The indicated population is described as adults with obesity, or adults with overweight who have at least one weight-related comorbid condition, for chronic weight management in conjunction with reduced-calorie diet and increased physical activity. The announcement summarizes a once-daily oral regimen with stepwise dose escalation, reflecting titration over time rather than a fixed-dose approach.

Safety information is presented as a high-level labeling summary. The FDA states that Foundayo’s labeling includes a boxed warning for thyroid C-cell tumors, consistent with the GLP-1 receptor agonist class. The release lists commonly reported adverse reactions, including gastrointestinal events (such as nausea, constipation, diarrhea, vomiting, and abdominal pain), as well as headache and fatigue. It also references additional warnings and precautions and notes, per labeling, that the product should not be used in combination with another GLP-1 receptor agonist.

On payer, access, and pricing topics, the announcement focuses on the regulatory action and selected labeling elements rather than commercialization details. It reports the approval and expedited review context but does not include information on pricing, payer coverage, formulary placement, prior authorization, or availability timelines.